| 李婉贞,李寅瑞.药品微小修改被授予专利的挑战及应对[J].陕西学前师范学院学报,2017,33(6):134-138 |
| 药品微小修改被授予专利的挑战及应对 |
| The Challenge and Countermeasure of Patent Granting of Slightly Modified Drug |
| 投稿时间：2017-01-13 修订日期：2017-03-03 |
| DOI：10.11995/j.issn.2095-770X.2017.06.030 |
| 中文关键词: 药品 微小修改 专利权 |
| 英文关键词: drug slight modification patent |
| 基金项目:安徽财经大学研究生科研创新基金项目（ACYC2015234） |
|
| 摘要点击次数: 1409 |
| 全文下载次数: 866 |
| 中文摘要: |
| 跨太平洋战略经济伙伴关系协定（TPP）被披露的最后文本显示，专利被授予范围扩至药品的微小修改，此举将直接导致药品专利的保护期限被变相延长，保护标准提高，仿制药品更加难以进入公众领域。这是大国主导下利益博弈的结果，忽视了普通群众的利益，影响了人的生命权、健康权，有违利益衡平的原则，缺乏正当性。我国作为发展中国家，不宜盲目跟随TPP的相关规定，应当主动利用世界卫生组织、世界知识产权组织等国际组织的力量，积极推动知识产权下人权保障的议程，完善强制许可制度，同时提高医保水平。 |
| 英文摘要: |
| The final text of The Trans-Pacific Partnership (TPP) reveals that the scope of the granted patent extends to slightly modified drugs, and it will directly cause that the term of protection will be prolonged, and generic drugs are more difficult to enter into the public domain. This is the result of the interests of the game under the leading power, which ignores the interests of the people in the lower social status, affecting people’s life right and health right, violating the principle of equity, and lacking legitimacy. As a developing country, our nation should not follow the relevant provisions of TPP, and should use the strength of WIPO and other international organizations to promote the protection of the human rights agenda under the intellectual property rights, and improve compulsory licensing system and the level of health insurance. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
